Myxedema coma, the extreme manifestation of hypothyroidism, is an uncommon but potentially lethal condition. Patients with hypothyroidism may exhibit a number of physiologic alterations to compensate for the lack of thyroid hormone. If these homeostatic mechanisms are overwhelmed by factors such as infection, the patient may decompensate into myxedema coma. Patients with hypothyroidism typically have a history of fatigue, weight gain, constipation and cold intolerance. Physicians should include hypothyroidism in the differential diagnosis of every patient with hyponatremia. Patients with suspected myxedema coma should be admitted to an intensive care unit for vigorous pulmonary and cardiovascular support. Most authorities recommend treatment with intravenous levothyroxine (T4) as opposed to intravenous liothyronine (T3). Hydrocortisone should be administered until coexisting adrenal insufficiency is ruled out. Family physicians are in an important position to prevent myxedema coma by maintaining a high level of suspicion for hypothyroidism. (Am Fam Physician 2000;62:2485-90.)
Myxedema coma is an extreme complication of hypothyroidism in which patients exhibit multiple organ abnormalities and progressive mental deterioration. The term myxedema is often used interchangeably with hypothyroidism and myxedema coma. Myxedema also refers to the swelling of the skin and soft tissue that occurs in patients who are hypothyroid. Myxedema coma occurs when the body's compensatory responses to hypothyroidism are overwhelmed by a precipitating factor such as infection.
A common misconception is that a patient must be comatose to be diagnosed with myxedema coma. However, myxedema coma is a misnomer because most patients exhibit neither the nonpitting edema known as myxedema nor coma.(1,2) Instead, the cardinal manifestation of myxedema coma is a deterioration of the patient's mental status.
When only comatose patients are considered, myxedema coma is exceedingly rare: one study reports 200 cases between 1953 and 1996.(3) Applying a broader definition results in a significantly higher number of cases. While the actual prevalence of myxedema coma is unknown, its lethal nature demands recognition. Even with early detection and appropriate treatment, mortality ranges from 30 to 60 percent.(3,4) Family physicians must be alert to the possibility of undiagnosed hypothyroidism in their patients.
Hypothyroidism is four times more common in women than in men; 80 percent of cases of myxedema coma occur in females.(5,6) Myxedema coma occurs almost exclusively in persons 60 years and older.(5) More than 90 percent of cases occur during the winter months.(6) This seasonal presentation is probably due to age-related loss of the ability to sense temperature and lower heat production secondary to hypothyroidism.(7)
Patients with myxedema coma usually have longstanding hypothyroidism, although it may not have been previously diagnosed. They often demonstrate classic symptoms of hypothyroidism: fatigue; constipation; weight gain; cold intolerance; a deep voice; coarse hair; and dry, pale, cool skin. However, elderly patients with hypothyroidism often have atypical presentations, such as decreased mobility,(8) and some patients with compensated hypothyroidism are asymptomatic.(9)
Decompensation into myxedema coma occurs when the hypothyroid patient's homeostatic mechanisms are disrupted. Multiple factors can precipitate myxedema coma (Table 1).(1-3,10-14) Some of the more common precipitating factors include infections, particularly pneumonia and urosepsis, and certain medications. Another potential risk factor is failure to reinstate thyroid replacement therapy during hospitalization.
Physical findings in myxedema coma (Table 2) may include the classic myxedematous face, which is characterized by generalized puffiness, macroglossia, ptosis, periorbital edema, and coarse, sparse hair. Nonpitting edema of the lower extremities is sometimes present. The findings from a thyroid examination are usually normal, but a goiter may be present in some patients. The presence of a scar on the neck might suggest postsurgical hypothyroidism and may be an important clue in the diagnosis of a patient who is comatose. A neurologic examination may reveal decreased reflex tendon relaxation and will invariably reveal altered mentation.
All patients with myxedema coma display deterioration of their mental status. This decline may be subtle, manifesting as apathy, neglect or a decrease in intellectual function; more obvious changes include confusion, psychosis and, rarely, coma. While all patients with myxedema coma present with some degree of mental status change, few progress to coma. When there is doubt about a change in mental status, formal mental status testing should be performed.
Physicians should also be alert to the possibility of depression in the seemingly demented patient and perform depression screening in any patient with mental status changes. Lumbar puncture may also be clinically appropriate.
Another common clinical feature of myxedema coma is hypothermia. The patient's temperature is usually less than 35.5[degrees]C (95.9[degrees]F).(13) Conditions that may precipitate myxedema coma such as hypoglycemia and cold exposure may exacerbate the hypothermia. However, the patient's temperature is not always an accurate diagnostic aid because some patients present with a normal temperature.
BLOOD PRESSURE CHANGES
Patients with compensated hypothyroidism often exhibit diastolic hypertension. Decreased oxygen consumption and lowered body temperature result in peripheral vasoconstriction and central shunting.(2) Only when the patient has begun to decompensate do these neurovascular mechanisms fail. The patient may then display the hypotension characteristically associated with myxedema coma. Bradycardia, low cardiac output and overall blood volume deficit frequently exacerbate the hypotension.
Hypoventilation in myxedema coma results from the body's decreased ventilatory response to hypoxia and hypercapnia.(15) Respiratory dysfunction may lead to sleep apnea,(16) and respiratory difficulties may be exacerbated by myxedematous infiltration of the tongue and pharynx.(15,17) The diaphragmatic weakness induced by hypothyroidism is reversed by thyroid hormone replacement.(16,18)
Multiple diagnostic findings are reported in patients with myxedema coma. This disorder impacts thyroid hormone levels, electrolyte levels, creatine kinase (CPK) levels and other laboratory values (Table 3).
Primary hypothyroidism results from the inability of the thyroid gland to produce adequate amounts of thyroid hormone. Typically, patients with myxedema coma have primary hypothyroidism manifested by low serum levels of thyroxine (T4) and triiodothyronine (T3) and a high thyroid stimulating hormone (TSH) level. However, primary hypothyroidism should be differentiated from secondary hypothyroidism, tertiary hypothyroidism and the low T4 level/low T3 level syndrome (euthyroid sick syndrome).
Secondary hypothyroidism is a result of pituitary dysfunction; tertiary hypothyroidism is caused by a hypothalamic abnormality. If the patient has hypopituitarism, the level of TSH is not increased. The findings of a low T4 level and low-normal or decreased TSH level mandate a search for pituitary abnormalities. However, a low level of serum T4 (and T3) with a normal TSH level may simply indicate that the patient's thyroid function tests have been altered as a result of illness unrelated to the thyroid (euthyroid sick syndrome).
The hyponatremia seen in myxedema coma is a result of decreased free water clearance. Elevated levels of antidiuretic hormone and/or diminished blood flow to the kidneys are believed to be responsible for the inability to excrete free water.(19,20) Hyponatremia is classically associated with a low serum osmolality. The level of serum creatinine is usually high, and while the level of calcium is generally low, it may be elevated.(21) Hypoglycemia may be a result of the down-regulation of metabolism seen in hypothyroidism2; it may also indicate the possibility of adrenal insufficiency.
ELEVATED CREATINE KINASE
Patients with myxedema coma may be misdiagnosed with myocardial infarction based on elevated CPK levels in association with nonspecific electrocardiographic (ECG) findings. Increased CPK and other transaminases are thought to result from altered membrane permeability.(22) Fractionation of the CPK reveals a skeletal muscle source. ECG changes include bradycardia, decreased voltages, non-specific ST and T changes, varying types of block and a prolonged QT interval. Conversely, physicians should be alert to the possibility of myocardial infarction as a triggering event for myxedema coma.
Arterial blood gases often reveal respiratory acidosis, hypoxia and hypercapnia. Mild leukopenia and a normocytic anemia are also frequently present. However, macrocytic anemia and pernicious anemia caused by associated immune dysfunction are sometimes present.(13,23) A chest radiograph may show cardiomegaly and pleural effusions. If cardiomegaly is present, an echocardiogram should be obtained to rule out a pericardial effusion. When performed, lumbar puncture typically reveals elevated protein levels(13,15,24) and a high opening pressure. Results of electroencephalography are nonspecific.(13)
The patient with myxedema coma should be admitted to the intensive care unit, and hypovolemia and electrolyte abnormalities corrected. Mechanical ventilation may be necessary. Cardiovascular status should be monitored carefully, especially after intravenous thyroid hormone replacement. Myocardial infarction must be ruled out and blood pressure stabilized. If possible, pressors and ionotropes should be avoided because of their tendency to provoke arrhythmias in the setting of intravenous thyroid replacement. Patients with hypothermia should be covered with regular blankets; the use of warming blankets should be avoided because the resulting peripheral dilatation may lead to hypotension and cardiovascular collapse.
THYROID HORMONE REPLACEMENT
Any patient with suspected myxedema coma should be treated presumptively with thyroid hormone. While there is concern regarding the precipitation of arrhythmias or myocardial infarction by administering large doses of intravenous levothyroxine, this concern must be balanced against T4's potentially life-saving and usually nondetrimental effect.(25)
While the necessity of intravenous thyroid hormone replacement is apparent, some controversy exists regarding the use and dosages of levothyroxine (T4) and liothyronine (T3). Because of the relatively small number of patients with myxedema coma, controlled studies comparing various dosages of T4 and T3 are lacking. Because T3 is more biologically active than T4, and because the conversion of T4 to T3 is suppressed in myxedema coma,(26,27) some have advocated T3 replacement. However, parental T3 is not only expensive and difficult to obtain, it may also contribute to increased mortality.(27)
Most authorities therefore recommend use of T4 alone.(2,7,13,14,27) An initial levothyroxine dose of 100 to 500 [micro]g administered intravenously should be followed by 75 to 100 [micro]g administered intravenously daily until the patient is able to take oral replacement. The lower initial dose should be administered to patients who are frail or have other comorbidities, particularly cardiovascular disease. Elderly patients typically require 100 to 170 [micro]g of oral levothyroxine daily.(13)
Infection is often the cause of the patient's decompensation; therefore, an infectious etiology should be sought with blood and urine cultures as well as a chest radiograph. Some authorities advocate empiric therapy with broad-spectrum intravenous antibiotics.(2)
Because of the possibility of secondary hypothyroidism and associated hypopituitarism, hydrocortisone should be administered until adrenal insufficiency has been ruled out. Hydrocortisone should be administered intravenously at a dosage of 100 mg every eight hours. Failure to treat with hydrocortisone in the face of adrenal insufficiency may result in the precipitation of adrenal crisis. A random cortisol level should be drawn prior to therapy, and if not depressed, the hydrocortisone can be discontinued without tapering. An adrenocorticotropic hormone stimulation test can be administered if clinically warranted.
The prognosis for patients with myxedema coma is difficult to define because of the small number of cases reported in the literature. The severity of the condition, however, is clear. One study reported a mortality rate of about 30 percent, while another suggests the mortality rate may be as high as 60 percent.(3,4) Factors associated with a poor prognosis include advanced age, bradycardia and persistent hypothermia.(27)
Family physicians should be alert for myxedema coma, particularly in elderly women with mental status changes who present during the winter months. An accurate diagnosis generally follows a careful history, physical examination and laboratory evaluation. The most important elements in treatment of myxedema coma are early recognition, presumptive thyroid hormone replacement, hydrocortisone and appropriate supportive care. While myxedema coma carries a significant mortality rate even with appropriate testing and treatment, an early diagnosis of hypothyroidism may well save a patient's life.
The author thanks the Baylor-Garland Family Practice Residency, Garland, Tex., the Faculty Development Center in Waco, Tex., and the University of Texas Southwestern Medical Center at Dallas for assistance with the manuscript, and Teresa Hanson for her research support.
(1.) Jordan RM. Myxedema coma: Pathophysiology, therapy, and factors affecting prognosis. Med Clin North Am 1995;79:185-94.
(2.) Nicoloff JT, LoPresti JS. Myxedema coma. A form of decompensated hypothyroidism. Endocrinol Metab Clin North Am 1993;22:279-90.
(3.) Werner SC, Ingbar SH, Braverman LE, Utiger RD. Werner & Ingbar's The thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lipincott Williams & Wilkins;2000.
(4.) Arlot S, Debussche X, Lalau JD, Mesmacque A, Tolani M, Quichard J, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med 1991;17:16-8.
(5.) Davis PJ, Davis FB. Hypothyroidism in the elderly. Compr Ther 1984;10:17-23.
(6.) Bailes BK. Hypothyroidism in elderly patients. AORN J 1999;69:1026-30.
(7.) Ballester JM, Harchelroad FP. Hypothermia: an easy-to-miss, dangerous disorder in winter weather. Geriatrics 1999;54:51-2,55-7.
(8.) Mintzer MJ. Hypothyroidism and hyperthyroidism in the elderly. J Fla Med Assoc 1992;79:231-5.
(9.) Robuschi G, Safran M, Braverman LE, Gnudi A, Roti E. Hypothyroidism in the elderly. Endocr Rev 1987;8:142-53.
(10.) Mazonson PD, Williams ML, Cantley LK, Dalldorf FG, Utiger RD, Foster JR. Myxedema coma during long-term amiodarone therapy. Am J Med 1984; 77:751-4.
(11.) Waldman SA, Park D. Myxedema coma associated with lithium therapy. Am J Med 1989;87:355-6.
(12.) Tsitouras PD. Myxedema coma. Clin Geriatr Med 1995;11:251-8.
(13.) Olsen CG. Myxedema coma in the elderly. J Am Board Fam Pract 1995;8:376-83. [Published errata appeared in J Am Board Fam Pract 1995;8:502 and 1996;9:63].
(14.) Smallridge RC. Metabolic and anatomic thyroid emergencies: a review. Crit Care Med 1992;20: 276-91.
(15.) Bardin CW, ed. Current therapy in endocrinology and metabolism. 6th ed. St. Louis, Mo: Mosby; 1997.
(16.) Orr WC, Males JL, Imes NK. Myxedema and obstructive sleep apnea. Am J Med 1981;70:1061-6.
(17.) Parving HH, Helin G, Garbarsch C, Johansen AA, Jensen BA, Helin P, et al. Acid glycosaminoglycans in myxoedema. Clin Endocrinol (Oxf) 1982;16: 207-10.
(18.) Martinez FJ, Bermudez-Gomez M, Celli BR. Hypothyroidism. A reversible cause of diaphragmatic dysfunction. Chest 1989;96:1059-63.
(19.) Derubertis FR, Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB. Impaired water excretion in myxedema. Am J Med 1971;51:41-53.
(20.) Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. Am J Med 1978;64:613-21.
(21.) Lowe CE, Bird ED, Thomas WC Jr. Hypercalcemia in myxedema. J Clin Endocrinol Metab1962;22: 261-7.
(22.) Doran GR, Wilkinson JH. The origin of the elevated activities of creatine kinase and other enzymes in the sera of patients with myxoedema. Clin Chim Acta 1975;62:203-11.
(23.) Horton L, Coburn RJ, England JM, Himsworth RL. The haematology of hypothyroidism. Q J Med 1976;45:101-23.
(24.) Mazzaferri EL, Surks MI. Recognizing the faces of hypothyroidism. Hosp Pract (Off Ed) 1999;34:93-6, 101-5,109; discussion 109-10.
(25.) Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986;63:1-8.
(26.) Pereira VG, Haron ES, Lima-Neto N, Medeiros-Neto G. Management of myxedema coma: report on three successfully treated patients with nasogastric or intravenous administration of triiodothyronine. J Endocrinol Invest 1982;5:331-4.
(27.) Hylander B, Rosenqvist U. Treatment of myxoedema coma--factors associated with fatal outcome. Acta Endocrinol (Copenh) 1985;108:65-71.
CRISTEN RHODES WALL, M.D., is an assistant professor in the Department of Family Practice and Community Medicine at the University of Texas Southwestern Medical Center at Dallas, where she received her medical degree. Dr. Wall is a recent graduate of the Baylor-Garland Family Practice Residency Program, Garland, Tex.
Address correspondence to Cristen R. Wall, M.D., University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9067. Reprints are not available from the author.
COPYRIGHT 2000 American Academy of Family Physicians
COPYRIGHT 2001 Gale Group